Petros Pharmaceuticals, Inc. booked $5.1M in FY2024 revenue, contracting 12% year over year — slower than 70% of Healthcare companies we track, at a 37.4% net margin.
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.